Abiopharma

🔍 Miller Larry R. (Executive)

Company: SIGA TECHNOLOGIES INC (SIGA)

Report Date: 2026-03-25

Detailed Transactions and Holdings:

• Acquired 6,920 shares of Common Stock, par value $.0001 per share (Direct)
  Date: 2026-03-25 | Code: M | equity_swap_involved: false | shares_owned_after: 55,438.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,526 shares of Common Stock, par value $.0001 per share at $4.99 per share (Direct)
  Date: 2026-03-25 | Code: F | equity_swap_involved: false | shares_owned_after: 51,912.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 6,920 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-25 | Code: M | equity_swap_involved: false | shares_owned_after: 6,921.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3

Footnotes:

• F1: Represents the acquisition of Common Stock from the vesting of one-third of the restricted stock units ("RSUs") granted on March 25, 2024.
• F2: Represents the withholding by the Issuer of shares of Common Stock (based on $4.99 per share, the closing stock price on March 25, 2026) to satisfy tax withholding obligations associated with the vesting of RSUs and the consequent issuance of Common Stock.
• F3: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant.